Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome

Last updated: August 22, 2024
Sponsor: The Canadian College of Naturopathic Medicine
Overall Status: Active - Recruiting

Phase

2/3

Condition

Depression

Post-partum Depression

Treatment

Prebiotics

Fish oil

Diet Quality

Clinical Study ID

NCT06074250
CCNMREB049
  • Ages 18-43
  • Female

Study Summary

Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies. The adverse outcomes extend beyond maternal well-being to long-term deficits in children and families. The gut-brain axis is a newly recognized key player in mental health disorders. Specifically, the microbial composition of the gut along with their metabolites are directly involved in disease onset and course. Recent clinical studies have identified diet as the most powerful environmental factor in manipulating gut microbiome. Given vulnerability and resistance of pregnant women to pharmacotherapy, particularly in those with a predisposition to mood disorders, as well as pregnant women's high motivation and commitment to improving gestational diet, a dietary/supplemental intervention to 'optimize' gut microbiome, is a favored approach in disease management. The study investigators aim to exploit microbial responsiveness to diet together with this maternal motivation, to alter the risk and severity of a universal public health concern that has dire and long-term consequences for new moms and their children.

The investigators of this trial, will first study the challenges in pursuing a study aimed at changing the microbiome of pregnant women with a history of mood disorders. Pregnant women in their second trimester will be recruited. Each will be assigned or randomized to one of four groups that will use a combination of diet, supplementation with probiotics, fish oil or no intervention. Each participant will meet with the study team virtually every 3 months until 1 year after delivery. At each study visit participants will be required to complete some questionnaires about their food intake, mood, and other health related measures and will provide a stool sample using the stool collection kits provided.

The findings from this study will help strategize for a larger study that will allow for comparison of the effects of diet, and/or supplementation with Omega-3 Fatty Acids (O3FA) and probiotics on the microbiome and the onset and severity of PDA.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Women 18-43 years old

  • 12-35 weeks of gestation

  • Non-smoker/alcohol/recreational drug user

  • Financially stable

  • Clinical diagnosis of lifetime depression/anxiety or PDA but currently well

  • English speaking

Exclusion

Exclusion Criteria:

  • Body Mass Index (BMI)≥30

  • Low income (unable to afford basic daily needs (i.e., shelter, food, etc.)

  • Diagnosis with other major mental health disorders (Bipolar, Psychosis, Addiction,Schizophrenia);

  • Diagnosis with other severe medical conditions (i.e. epilepsy, neurologicaldisorders, etc.)

  • Allergies to fish oils/ingredients in supplements

  • Conditions that require repeated/chronic antibiotic usage

  • Having a child with significant mental/physical disability

  • Single mothers without any kind of family support,

  • Cigarette, alcohol and recreational drug users

  • Women unwilling to switch to study product(s)

  • Multiparous women with young children (i.e. one or more children less than 4 yearsof age at the time of delivery)

  • Non-English Readers/Speakers

Study Design

Total Participants: 100
Treatment Group(s): 4
Primary Treatment: Prebiotics
Phase: 2/3
Study Start date:
August 15, 2024
Estimated Completion Date:
March 31, 2028

Study Description

Pregnant women with a history of anxiety and/or depression & currently stable, will be recruited and randomized or assigned to one of four study groups. A total of 100 will be recruited and required to complete six study visits, one every 3 months. At each visit, data on dietary intake, mental health scores, and stool samples will be collected using appropriate tools. All visits will be completed virtually, unless participants need in-person follow-ups.

The final visit is expected to occur between 9-12 months after delivery. The primary outcome for this study is feasibility, measured by: recruiting the targeted number of participant within the anticipated timeframe, and completion of at least 4 of the 6 visits by each participant.

Connect with a study center

  • Sunnybrook Health Science Center

    Toronto, Ontario M4N 3M5
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.